Risperidon microspheres - The renaissance of neuroleptic depot therapy;Risperidon microspheres: Die renaissance der neuroleptischen depottherapie

Psychopharmakotherapie

Volumn 9, Issue 4, 2002, Pages 133-139

  Messer, Thomas ^a   Pajonk, Frank Gerald ^b   Heger, Steffen ^c   Schmaurß, Max ^a  

^a Bezirkskrankenhaus Augsburg   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

Author keywords

Atypical antipsychotic; Compliance; Depot neuroleptic; Pharmacology; Relapse prevention; Risperidone microspheres; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE;

COMPREHENSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TOLERABILITY; DRUG TOLERANCE; GERMANY; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; OUTCOMES RESEARCH; PARAMETER; PATIENT COMPLIANCE; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT INDICATION;

EID: 0036859109     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Adams CE, Fenton MKP, Quraishi S, David AS, et al. Systematic meta-review of depot antispychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9.
2. Barnes TRE, Curson DA. Long term depot antipsychotics. A risk-benefit assessment. Drug Safety 1994;10:464-79.
3. Bloch Y, Mendlovic S, Stupinsky S, Altshuler A, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855-9.
4. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine 1992;22:787-97.
5. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-8.
6. Cramer JA, Rosenheck R. Compliance with medication regimes for mental and physical disorders, Psychiatric Services 1998;49:196-201.
7. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
8. Csernansky JG, Schuchart EK. Relapse and rehospitalization rates in patients with schizophrenia. CNS Drugs 2002;16;473-84.
9. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73.
10. Döring S, Müller E, Köpcke W, Pietzcker A, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98.
11. Donohoe G, Owens N, O'Donell C, Burke T. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: A discriminant function anlaysis. Eur Psychiatry 2001;16:293-8.
12. Eerdekens M, Fleischhacker WW, Xie Y, Beauclair L, et al. Long-term safety of long-acting risperidone micropheres. Schizophr Res 2002;53(Suppl):174-5.
13. Fleischhacker WW, Meise U, Günther V, Kurz M. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand 1994;89(Suppl 382):11-5.
14. Foster RH, Goa KL. Risperidone. A pharmacoeconomic drug evaluation. Pharmacoeconomics 1998;14:97-133.
15. Franz M, Lis S, Plüddemann K, Gallhofer B. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-5.
16. Fuller MA, Shermock KM, Secic M, Laich JS, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatric Services 2002;53:855-60.
17. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients - The interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985;18:235-9.
18. Gaebel W. Early pharmacotherapeutic intervention in relapse prevention: Fundamentals, indication and management. In: Brenner HD, Böker W, Genner R, eds. Towards Comprehensive therapy for Schizophrenia. Seattle, Toronto, Bern, Göttingen: Hogrefe und Huber, 1997:195-208.
19. Gaebel W, Jänner M, Frommann N, Pietzcker A, et al. First vs multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002;53:145-59.
20. Gaebel W, Falkai P, DGPPN, Hrsg. Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1, Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff Verlag, 1998.
21. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65-8.
22. Hagström L, Hansson BM. Practical handling aspects of long-lasting risperidone microspheres (Risperdal Consta): An attitude survey. Nord J Psychiatry 2002;56:18.
23. Haro JM, Egnell ET, Frewer P, Novick D, et al. Schizophrenia treatment in Europe: Country differences in the SOHO study. Eur Psychiatry 2002;17(Suppl):150.
24. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-61.
25. Helmchen H. Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 1978;49:534-8.
26. Hirsch SR, Gaind R, Rohde PD, Stevens BC, et al. Outpatients maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial. BMJ 1973;1:633-7.
27. Hogarty GE, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-years relapse rates. Arch Gen Psychiatry 1974;31:603-8.
28. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991;48:340-7.
29. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, et al. Risk of tadive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-65.
30. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;(Suppl 4):52-6.
31. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
32. Kane JM, Eerdekens M, Keith S, Lesem M, et al. Efficacy and safety of a novel long-acting risperidone formulation. Schizophr Res 2002;53(Suppl):174-5.
33. Kapfhammer HP, Rüther E. Depot-Neuroleptika. Berlin, Heidelberg, New York: Springer, 1987.
34. Kent S, Yellowlees P. Psychiatric and social reasons for frequent rehospitalization. Hosp Community Psychiatry 1994;45:347-50.
35. Kissling W. Neuroleptic relapse prevention. In: Kissling W. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia, Proceedings of a Consensus Conference. Berlin, Heidelberg, New York: Springer, 1991:50-2.
36. Lecompte D, Cookson RF. The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited. Int J Psych Clin Pract 1999;3:3-9.
37. Leff J, Wing JK. Trial of maintenance therapy of schizophrenia. BMJ 1971;3:599-604.
38. Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55:5-12.
39. Lindström E, Eriksson B, Hellgren A, von Knorring L, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-12.
40. Lingjoerde O. Some pharmacological aspects of depot neuroleptics. Acta Psychiatr Scand 1973;246:9-14.
41. Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesia and antipsychotics: A review. Eur Psychiatry 2002;17:129-38.
42. Llorca PM, Devos E, Eerdekens M, Duchesne I, et al. Re-hospitalisation rates with long-acting risperidone injection are lower than those reported for other antipsychotics. XXIII. Collegium Internationale Neuro-Psychopharmacologicum (CINP), Montreal, 23. bis 27. Juni 2002 [Poster]. Int J Neuropsychopharmacol 2002;5(Suppl 1):189.
43. Möller HJ, Schmauß M. Arzneimitteltherapie in der Psychiatrie. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1996.
44. Müller HJ, Laux G, Kapfhammer HP. Psychiatrie und Psychotherapie. Berlin, Heidelberg, New York: Springer, 2000.
45. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000;1:204-14.
46. Müller P. Die patienten und das ergebnis der rezidivprophylaxe. In: Müller P, Hrsg. Zur Rezidivprophylaxe Schizophrener Psychosen. Stuttgart: Enke, 1982:15-23.
47. Naber D. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Aufl. Bremen: Uni Med Verlag, 2000.
48. Olfson M, Mechanic D, Hansell S, Boyer CA, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Services 2000;51:216-22.
49. Pajonk FG, Messer T, Heger S, Schmauß M. Klinisches Profil von Risperidon Microspheres - Das erste atypische Antipsychotikum in Depotform. Psychopharmakotherapie 2002;9:140-6.
50. Pietzcker A, Popenberg A, Schley J, Müller-Oerlinghausen B. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients. Arch Psychiatr Nervenkr 1981;229:315-29.
51. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9.
52. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. Relapse rate after one year. Arch Gen Psychiatry 1977;34:43-7.
53. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
54. Schwabe U, Pfaffrath D. Arzneiverordnungs-Report 2001. Berlin, Heidelberg: Springer Verlag, 2001.
55. Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry 1984;45:3-4.
56. Sullivan G, Young AS, Morgenstern H, et al. Behaviours as risk factors for rehospitalization: Implications for predicting and preventing admissions among the seriously mentally ill. Soc Psychiatry Psychiatr Epidemiol 1997;32:185-90.
57. Tegeler J, Lehmann E, Stockschlaeder M. Zur wirksamkeit der langfristigen ambulanten behandlung schizophrener mit depot- und langzeit-neuroleptika. Nervenarzt 1980;51:654-61.
58. Valenstein M, Copeland LA, Owen R, Blow FG, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62:545-51.
59. Walburn J, Gray R, Gournay K, Quraishi S, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7.
60. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997;68:377-92.
61. Westermayer JF, Harrow M. Prognosis and outcome using broad (DSM-II) and narrow (DSM-III) concepts of schizophrenia. Schizophr Bull 1984;10:624-37.
62. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: Relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 2000;15:175-80.